Search Result

Isoforms Recommended:	FOXO3

Results for "

FOXO3

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (3) Amyloid-β (2) Apoptosis (5) Autophagy (2) Cytochrome P450 (1) EGFR (2) FOXO (3) Interleukin Related (1) Mitophagy (1) MMP (1) Organoid (2) Phosphatase (1) Phosphodiesterase (PDE) (2) PI3K (1) PINK1/Parkin (1) Potassium Channel (1) Pyroptosis (1) Reactive Oxygen Species (ROS) (1) Reference Standards (1) Sirtuin (1) Small Interfering RNA (siRNA) (3) Tau Protein (1) Xanthine Oxidase (1) YTHDF (1)
By Research Areas:	Cancer (10) Endocrinology (1) Inflammation/Immunology (2) Metabolic Disease (1) Neurological Disease (4)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

Inhibitors & Agonists

Natural
Products

Recombinant Proteins

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B1462

Chlorzoxazone 3 Publications Verification	Cytochrome P450 Potassium Channel FOXO Amyloid-β	Neurological Disease Inflammation/Immunology
Chlorzoxazone is a SK-type potassium channel activator. Chlorzoxazone modulates *FOXO3* phosphorylation and Aβ. Chlorzoxazone enhances immunosuppression, attenuates vasoconstriction, attenuates cognitive deficits, and improves experimental autoimmune encephalomyelitis ^[3] .

HY-142125

Broussochalcone A	Xanthine Oxidase Reactive Oxygen Species (ROS) Apoptosis	Inflammation/Immunology Cancer
Broussochalcone A is an antioxidant and an inhibitor of Xanthine Oxidase (IC₅₀=2.21 μM), with free radical scavenging activity. Broussochalcone A inhibits iron-induced lipid peroxidation and nitric oxide synthesis in lipopolysaccharide (LPS) -activated macrophages. Broussochalcone A also induces Apoptosis of human renal carcinoma cells by increasing ROS levels and activating FOXO3 signaling pathways .

HY-154919

DC-Y13-27 4 Publications Verification	YTHDF FOXO MMP Pyroptosis Interleukin Related	Endocrinology Cancer
DC-Y13-27 is a DC-Y13 derivative and YTHDF2 inhibitor (K_D: 37.9 μM). DC-Y13-27 inhibits YTHDF2, restores *FOXO3* and TIMP1 protein levels, and reduces *MMP1/3/7/9* expression. DC-Y13-27 induces Pyroptosis and increases IL-1β secretion. DC-Y13-27 reduces intervertebral disc degeneration and enhances the response to radiotherapy in colon cancer and melanoma. DC-Y13-27 has antitumor activity against breast cancer ^[3].

HY-148509

PhosTAC5	Others	Cancer
PhosTAC5 is a phosphorylation targeting chimera (PhosTAC) molecule composed of a linker with fivePEG groups. PhosTAC5 induces dephosphorylation of PDCD4 and FOXO3a .

HY-148508

PhosTAC3	Others	Cancer
PhosTAC3 is a phosphorylation targeting chimera (PhosTAC) molecule composed of a linker with three PEG groups. PhosTAC3 induces dephosphorylation of PDCD4 and FOXO3a .

HY-RS05070

FOXO3 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
FOXO3 Human Pre-designed siRNA Set A contains three designed siRNAs for FOXO3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

FOXO3 Human Pre-designed siRNA Set A FOXO3 Human Pre-designed siRNA Set A

HY-RS16632

Foxo3 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Foxo3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Foxo3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Foxo3 Mouse Pre-designed siRNA Set A Foxo3 Mouse Pre-designed siRNA Set A

HY-RS23067

Foxo3 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Foxo3 Rat Pre-designed siRNA Set A contains three designed siRNAs for Foxo3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Foxo3 Rat Pre-designed siRNA Set A Foxo3 Rat Pre-designed siRNA Set A

HY-174806

Y040-7904	Mitophagy PINK1/Parkin Amyloid-β	Neurological Disease
Y040-7904 is a mitophagy activator. Y040-7904 enhances mitophagy by promoting mitochondria transport to autophagosomes and the fusion of autophagosomes with autolysosomes. Y040-7904 induces mitophagy through the SIRT1/FoxO3 pathway. Y040-7904 upregulates the levels of Parkin, PINK1, and LC3II/I. Y040-7904 reduces amyloid-β (Aβ) accumulation in both in vitro and in vivo models of Alzheimer’s disease.

HY-162050

8AQ−Cu−5Iu	Sirtuin	Neurological Disease
8AQ?Cu?5Iu is an activator of SIRT1. 8AQ?Cu?5Iu exhibits neuroprotective effects by modulating the *SIRT1/3-FOXO3a* signaling pathway. 8AQ?Cu?5Iu can used in study attenuating neurodegenerative diseases .

HY-153347

JY-2 1 Publications Verification	FOXO	Metabolic Disease
JY-2 is a moderately selective and orally active Forkhead transcription factor forkhead box O1 (FoxO1) inhibitor that inhibits FoxO1 transcriptional activity with an IC₅₀ of 22 μM. JY-2 shows moderate inhibition against FoxO3a and FoxO4. JY-2 shows anti-diabetic activity .

HY-145232

PhosTAC7 3 Publications Verification	Phosphatase Tau Protein	Neurological Disease Cancer
PhosTAC7 is a heterobifunctional molecule named as a Phosphorylation Targeting Chimera (PhosTAC). PhosTAC7 can dephosphorylate the PDCD4 protein, *FOXO3a* protein, and Tau protein by recruiting serine/threonine protein phosphatase 2A (PP2A). PhosTAC7 offers the advantage of selectively modulating the phosphorylation state of individual target proteins, making it a promising tool for research in cancer and tau protein-related neurodegenerative diseases .

HY-16558

Butein 4 Publications Verification 2’,3,4,4’-tetrahydroxy Chalcone	EGFR Autophagy Apoptosis Phosphodiesterase (PDE)	Cancer
Butein is a cAMP-specific PDE inhibitor with an IC₅₀ of 10.4 μM for PDE4 . Butein is a specific protein tyrosine kinase inhibitor with IC₅₀s of 16 and 65 μM for EGFR and p60 ^c-src in HepG2 cells . Butein sensitizes HeLa cells to Cisplatin through AKT and ERK/p38 MAPK pathways by targeting FoxO3a ^[3]. Butein is a SIRT1 activator (STAC).

HY-15186

Ipatasertib Maximum Cited Publications 51 Publications Verification GDC-0068; RG7440	Organoid Akt Apoptosis	Cancer
Ipatasertib (GDC-0068) is an orally active, highly selective and ATP-competitive pan-Akt inhibitor with IC₅₀ values of 5, 18, 8 nM for *Akt1/2/3, respectively. Ipatasertib synchronously activates FoxO3a and NF-κB through inhibition of Akt* leading to p53-independent activation of PUMA. Ipatasertib also induces apoptosis in cancer cells and inhibits tumor growth in xenograft mouse models .

HY-15186C

Ipatasertib tosylate GDC-0068 tosylate; RG7440 tosylate	Organoid Akt Apoptosis	Cancer
Ipatasertib (GDC-0068) tosylate is an orally active, highly selective and ATP-competitive pan-Akt inhibitor with IC₅₀ values of 5, 18, 8 nM for *Akt1/2/3, respectively. Ipatasertib tosylate synchronously activates FoxO3a and NF-κB through inhibition of Akt* leading to p53-independent activation of PUMA. Ipatasertib tosylate also induces apoptosis in cancer cells and inhibits tumor growth in xenograft mouse models .

HY-16558R

Butein (Standard) 2’,3,4,4’-tetrahydroxy Chalcone (Standard)	Reference Standards EGFR Autophagy Apoptosis Phosphodiesterase (PDE)	Cancer
Butein (Standard) is the analytical standard of Butein. This product is intended for research and analytical applications. Butein is a cAMP-specific PDE inhibitor with an IC50 of 10.4 μM for PDE4 . Butein is a specific protein tyrosine kinase inhibitor with IC50s of 16 and 65 μM for EGFR and p60c-src in HepG2 cells . Butein sensitizes HeLa cells to Cisplatin through AKT and ERK/p38 MAPK pathways by targeting FoxO3a ^[3]. Butein is a SIRT1 activator (STAC).

HY-116604

RLX PD 139530	PI3K Akt	Cancer
RLX (PD 139530) is a PI3K/Akt/FoxO3a signaling inhibitor, possessing significant therapeutic potential in experimental colon cancer. RLX can effectively modulate the tumor microenvironment, enhancing the efficacy of cancer immunotherapy. RLX demonstrates the ability to improve the retention time of therapeutic agents within the tumor microenvironment by utilizing advanced nanoparticle delivery systems. RLX can be integrated with various treatment modalities, such as chemotherapy and radiotherapy, to enhance overall tumor therapy effectiveness. RLX highlights the necessity for further research into the tumor microenvironment’s dynamics to develop more tailored treatment approaches for diverse tumor types.

Broussochalcone A	Structural Classification Chalcones Flavonoids Source classification Plants Moraceae Broussonetia papyrifera (Linnaeus) L'Heritier ex Ventenat	Xanthine Oxidase Reactive Oxygen Species (ROS) Apoptosis
Broussochalcone A is an antioxidant and an inhibitor of Xanthine Oxidase (IC₅₀=2.21 μM), with free radical scavenging activity. Broussochalcone A inhibits iron-induced lipid peroxidation and nitric oxide synthesis in lipopolysaccharide (LPS) -activated macrophages. Broussochalcone A also induces Apoptosis of human renal carcinoma cells by increasing ROS levels and activating FOXO3 signaling pathways .

Butein 4 Publications Verification 2’,3,4,4’-tetrahydroxy Chalcone	Structural Classification Chalcones Flavonoids other families Classification of Application Fields Anti-aging Source classification Phenols Polyphenols Plants Disease Research Fields Cancer	EGFR Autophagy Apoptosis Phosphodiesterase (PDE)
Butein is a cAMP-specific PDE inhibitor with an IC₅₀ of 10.4 μM for PDE4 . Butein is a specific protein tyrosine kinase inhibitor with IC₅₀s of 16 and 65 μM for EGFR and p60 ^c-src in HepG2 cells . Butein sensitizes HeLa cells to Cisplatin through AKT and ERK/p38 MAPK pathways by targeting FoxO3a ^[3]. Butein is a SIRT1 activator (STAC).

Butein (Standard) 2’,3,4,4’-tetrahydroxy Chalcone (Standard)	Structural Classification Chalcones Flavonoids other families Source classification Phenols Polyphenols Plants	Reference Standards EGFR Autophagy Apoptosis Phosphodiesterase (PDE)
Butein (Standard) is the analytical standard of Butein. This product is intended for research and analytical applications. Butein is a cAMP-specific PDE inhibitor with an IC50 of 10.4 μM for PDE4 . Butein is a specific protein tyrosine kinase inhibitor with IC50s of 16 and 65 μM for EGFR and p60c-src in HepG2 cells . Butein sensitizes HeLa cells to Cisplatin through AKT and ERK/p38 MAPK pathways by targeting FoxO3a ^[3]. Butein is a SIRT1 activator (STAC).

Cat. No.	Compare	Product Name	Species	Source

HY-P701170

	FOXO3 Protein, Human (HEK293, His) AF6q21; FKHRL1; FKHRL1P2; FOXO2; FOXO3A	Human	HEK293
	The FOXO3 protein is a multifaceted transcriptional activator that regulates apoptosis, autophagy, and post-transcriptional MYC control. It actively regulates autophagy in skeletal muscle and induces autophagy gene expression under starvation conditions. FOXO3 Protein, Human (HEK293, His) is the recombinant human-derived FOXO3 protein, expressed by HEK293 , with C-10*His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P80677

	FOXO3A Antibody (YA428) FOXO3; FKHRL1; FOXO3A; Forkhead box protein O3; AF6q21 protein; Forkhead in rhabdomyosarcoma-like 1	WB	Human
	FOXO3 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 71 kDa, targeting to FOXO3. It can be used for WB assays with tag free, in the background of Human.

HY-P80817

	*Phospho-FOXO3A (Ser253) Antibody (YA197)* FOXO3; FKHRL1; FOXO3A; Forkhead box protein O3; AF6q21 protein; Forkhead in rhabdomyosarcoma-like 1	WB	Human, Mouse, Rat
	Phospho-FOXO3A (Ser253) Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 71 kDa, targeting to Phospho-FOXO3A (Ser253). It can be used for WB assays with tag free, in the background of Human, Mouse, Rat.

HY-P80461

	*Phospho-FOXO3A(Ser253) Antibody (YA196)*	WB, IHC-P	Human, Mouse, Rat
	Phospho-FOXO3a(Ser253) Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 71 kDa, targeting to Phospho-FOXO3a(S253). It can be used for WB,IHC-P assays with tag free, in the background of Human, Mouse, Rat.

HY-P86548

	*Phospho-FOXO3A(Ser253) Antibody (YA6240)* FOXO3; FKHRL1; FOXO3A; Forkhead box protein O3; AF6q21 protein; Forkhead in rhabdomyosarcoma-like 1	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	Phospho-FOXO3A(Ser253) Antibody (YA6240) is a rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to phosphorylated FOXO3A (Ser253). It can be applicated for WB, IHC-P, ICC/IF, IP, ELISA assays, in the background of human, mouse, rat.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

FOXO3 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
FOXO3 Human Pre-designed siRNA Set A contains three designed siRNAs for FOXO3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Foxo3 Mouse Pre-designed siRNA Set A		siRNAs Mouse Pre-designed siRNA Sets
Foxo3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Foxo3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Foxo3 Rat Pre-designed siRNA Set A		siRNAs Rat Pre-designed siRNA Sets
Foxo3 Rat Pre-designed siRNA Set A contains three designed siRNAs for Foxo3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks